Abstract:BACKGROUND:Oral ingestion, inhalation, and skin contact are important exposure routes for humans to uptake per- and polyfluoroalkyl substances (PFAS). However, nasal and dermal exposure to PFAS remains unclear, and accurately predicting internal body burden of PFAS in humans via multiple exposure pathways is urgently required.OBJECTIVES:We aimed to develop multiple physiologically based toxicokinetic (PBTK) models to unveil the route-specific pharmacokinetics and bioavailability of PFAS via respective oral, nasal, and dermal exposure pathways using a mouse model and sought to predict the internal concentrations in various tissues through multiple exposure routes and extrapolate it to humans.METHODS:Mice were administered the mixed solution of perfluorohexane sulfonate, perfluorooctane sulfonate, and perfluorooctanoic acid through oral, nasal, and dermal exposure separately or jointly. The time-dependent concentrations of PFAS in plasma and tissues were determined to calibrate and validate the individual and combined PBTK models, which were applied in single- and repeated-dose scenarios.RESULTS:The developed route-specific PBTK models successfully simulated the tissue concentrations of PFAS in mice following single or joint exposure routes as well as long-term repeated dose scenarios. The time to peak concentration of PFAS in plasma via dermal exposure was much longer (34.1-83.0 h) than that via nasal exposure (0.960 h). The bioavailability of PFAS via oral exposure was the highest (73.2%-98.0%), followed by nasal (33.9%-66.8%) and dermal exposure (4.59%-7.80%). This model was extrapolated to predict internal levels in human under real environment.DISCUSSION:Based on these data, we predict the following: PFAS were absorbed quickly via nasal exposure, whereas a distinct hysteresis effect was observed for dermal exposure. Almost all the PFAS to which mice were exposed via gastrointestinal route were absorbed into plasma, which exhibited the highest bioavailability. Exhalation clearance greatly depressed the bioavailability of PFAS via nasal exposure, whereas the lowest bioavailability in dermal exposure was because of the interception of PFAS within the skin layers. https://doi.org/10.1289/EHP11969.

Physiologically Based Pharmacokinetic Modeling for Chlorinated Paraffins in Rats and Humans: Importance of Biliary Excretion.

Development of Physiologically Based Toxicokinetic Models for 3-Monochloropropane-1,2-diol and Glycidol.

Integration of Metabolomics and Transcriptomics Reveals Short-Chain Chlorinated Paraffin-Induced Hepatotoxicity in Male Sprague-Dawley Rat.

Metabolomic Mechanisms of Short Chain Chlorinated Paraffins Toxicity in Rats.

Bayesian analysis of physiologically based toxicokinetic (PBTK) modeling for pentachlorophenol exposure in pregnant women

Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose, and dose route extrapolations

High-Throughput Determination And Characterization Of Short-, Medium-, And Long-Chain Chlorinated Paraffins In Human Blood

Development of Human Dermal PBPK Models for the Bisphenols BPA, BPS, BPF, and BPAF with Parallel-Layered Skin Compartment: Basing on Dermal Administration Studies in Humans

Biological Effects and Environmental Behaviors of Medium- and Long-Chain Chlorinated Paraffins: A Brief Review

The environmental distribution and toxicity of short-chain chlorinated paraffins and underlying mechanisms: Implications for further toxicological investigation

A review on biological occurrence, bioaccumulation, transmission and metabolism of chlorinated paraffins

Effects of exposure to chlorinated paraffins on human health: A scoping review

Physiologically Based Toxicokinetics (PBTK) Models for Pharmaceuticals and Personal Care Products in Wild Common Carp (cyprinus Carpio)

Toxic Effects and Toxicological Mechanisms of Chlorinated Paraffins: A Review for Insight into Species Sensitivity and Toxicity Difference

Using available in vitro metabolite identification and time course kinetics for β-chloroprene and its metabolite, (1-chloroethenyl) oxirane, to include reactive oxidative metabolites and glutathione depletion in a PBPK model for β-chloroprene

Characterization and health risks of short- and medium-chain chlorinated paraffins in the gas and size-fractionated particulate phases in ambient air

A physiologically based pharmacokinetic model of diethyl phthalates in humans

Global Environmental Fate of Short-Chain Chlorinated Paraffins: Modeling with a Single Vs. Multiple Sets of Physicochemical Properties.

Exploring Route-Specific Pharmacokinetics of PFAS in Mice by Coupling in Vivo Tests and Physiologically Based Toxicokinetic Models.

Mechanistic Middle-Out Physiologically Based Toxicokinetic Modeling of Transporter-Dependent Disposition of Perfluorooctanoic Acid in Humans

Cross-Model Comparison of Transcriptomic Dose-Response of Short-Chain Chlorinated Paraffins